Atara Biotherapeutics, Inc.
ATRA
$10.51
$0.292.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 23.14M | 120.77M | 151.93M | 188.67M | 199.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.14M | 120.77M | 151.93M | 188.67M | 199.73M |
| Cost of Revenue | 11.02M | 50.25M | 71.52M | 120.02M | 150.70M |
| Gross Profit | 12.12M | 70.52M | 80.41M | 68.65M | 49.03M |
| SG&A Expenses | 16.88M | 23.29M | 29.36M | 35.81M | 38.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.75M | 76.40M | 114.35M | 169.29M | 202.95M |
| Operating Income | -7.61M | 44.37M | 37.59M | 19.38M | -3.22M |
| Income Before Tax | -9.44M | 32.72M | 23.41M | 5.76M | -15.68M |
| Income Tax Expenses | 31.00K | 31.00K | 12.00K | -33.00K | -36.00K |
| Earnings from Continuing Operations | -9.47 | 32.69 | 23.40 | 5.80 | -15.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.47M | 32.69M | 23.40M | 5.80M | -15.64M |
| EBIT | -7.61M | 44.37M | 37.59M | 19.38M | -3.22M |
| EBITDA | -5.28M | 48.47M | 41.73M | 24.88M | 2.24M |
| EPS Basic | -0.67 | 3.16 | 2.22 | -0.39 | -3.69 |
| Normalized Basic EPS | -0.47 | 2.49 | 2.04 | 0.40 | -1.70 |
| EPS Diluted | -0.67 | 3.12 | 2.18 | -0.43 | -3.72 |
| Normalized Diluted EPS | -0.47 | 2.47 | 2.02 | 0.38 | -1.72 |
| Average Basic Shares Outstanding | 53.46M | 50.15M | 47.24M | 41.14M | 35.08M |
| Average Diluted Shares Outstanding | 53.58M | 50.35M | 47.44M | 41.34M | 35.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |